The approval of more vaccines will also give a boost to India's vaccination drive
The government, on April 13, said that it was fast-tracking approvals for foreign-made COVID-19 vaccines that had been granted emergency use authorisation in other countries.
India has so far approved three coronavirus vaccines. The Drug Controller General of India (DCGI) granted EUA to Sputnik V on April 13 while Oxford University-AstraZeneca and Bharat Biotech's Covaxin were approved in early January.
Read | Centre fast-tracks emergency approvals for foreign-made jabs
The matter was discussed in the last meeting of the National Expert Group on Vaccine Administration for COVID-19, the health ministry said.
"The group, after comprehensive deliberation, recommended that vaccines for COVID-19, which have been granted emergency approval for restricted use by US FDA, EMA, UK MHRA, PMDA Japan or listed in WHO (Emergency Use Listing) may be granted emergency use approval in India," it added.
Click here for Moneycontrol's COVID-19 Vaccine Tracker
The move is likely to enable faster approval for vaccines like Johnson and Johnson, which has been approved by the WHO.
The approval of more vaccines will also give a boost to India's vaccination drive as the health ministry allowed parallel bridging trials instead of mandatory local clinical trials.
Take a look at all the vaccines that could be rolled out in India soon
Johnson & Johnson
The Johnson & Johnson is a single-dose viral vector vaccine. The vaccine's storage temperature requirement is 2-8 degrees Celsius.
Overall, the vaccine prevented moderate to severe COVID-19 by 66.1 percent 28 days after the shot, but this rose to 85.4 percent when considering only severe disease.
The vaccine was approved by the WHO on March 12, 2021. The shot has also been approved in the US, Canada, Germany among other countries.
One of the most widely used, Pfizer and BioNTech's COVID-19 is already approved for use in the European Union, the United States, Canada, Britain and several other nations.
Clinical trials showed the vaccine -- which delivers instructions to the body to help the immune system identify and destroy COVID-19 molecules -- to be 95 percent effective in preventing illness and hospitalisation.
Pfizer/BioNTech used the messenger RNA (mRNA) technique for their vaccines. The downside is that the doses must be kept at ultralow temperatures, though Pfizer has managed to demonstrate that its vaccine can be kept up to two weeks at less intense cold.
Like Pfizer-BioNTech, Moderna's COVID-19 vaccine is based on genetic material or mRNA. The vaccine has a cold storage requirement of between -25°C and -15°C and is being sought by many countries.
The US-made vaccine, with a 94.1 percent efficacy rate, has been approved for use in the EU, North America, Britain, and several other nations, including Israel and Singapore.
The vaccine developed in China uses the traditional technique of injecting the deactivated virus in order to trigger an immune response.
Along with the United Arab Emirates, Hungary, Cambodia, Peru and Zimbabwe have all started administering the vaccine, which its makers say is 79 percent effective.
This Chinese-developed vaccine also uses a similar technique and is authorised in China, Chile, Brazil and Turkey. Others nations, including Ukraine and Uruguay, have pre-ordered doses.
The makers say it is 50 percent effective overall against COVID-19 (and 80 percent effective against severe illness), but trial results have not yet been made public.
WHO's decision on approval of China's Sinopharm and Sinovac jabs, along with the Moderna vaccine, is expected soon.
This Convidecia Chinese-made viral vector vaccine is a single-dose jab currently approved for use in China, Pakistan and Mexico. The overall efficacy for CanSino's stands at 65.28 percent after 28 days.Click here for Moneycontrol’s full coverage of the coronavirus pandemic